

Pharmacy and Therapeutic Committee updates

On August 17, 2018 and November 16, 2018, the Pharmacy and Therapeutic Committee (P&T) approved the following *Pharmacy Policies* applicable to Amerigroup. These policies were developed, revised or reviewed to support clinical coding edits. Several policies were edited to provide clarification only and are not included in the below listing.

The *Pharmacy Policies* will be made publicly available on the Amerigroup provider website on the publish date listed below. Visit [Pharmacy Clinical Criteria](#) to search for specific policies.

Existing precertification requirements have not changed. Please share this notice with other members of your practice and office staff.

Please note: For markets with pharmacy services carved out, the applicable listings below would be informational only.

Publish date	Pharmacy Policy number	Pharmacy Policy title	New, reviewed revised, annual review
August 17, 2018	ING-CC-0074	Akynzeo (fosnetupitant and palonosetron) for Injection	New
August 17, 2018	ING-CC-0077	Palynziq (pegvaliase-pqpz)	New
August 17, 2018	ING-CC-0081	Crysvita (burosumab-twza)	New
August 17, 2018	ING-CC-0082	Onpattro (patisiran)	New
August 17, 2018	ING-CC-0083	Aristada Initio (aripiprazole lauroxil)	New
October 9, 2018	ING-CC-0084	Tegsedi (inotersen)	New
August 17, 2018	ING-CC-0010	Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors	Revised
August 17, 2018	ING-CC-0013	Mepsevii (vestronidase alfa)	Revised
August 17, 2018	ING-CC-0026	Testosterone, Injectable	Revised
August 17, 2018	ING-CC-0027	Denosumab agents	Revised
August 17, 2018	ING-CC-0038*	Human Parathyroid Hormone Agents	Revised
November 16, 2018	ING-CC-0042*	Monoclonal Antibodies to Interleukin-17	Revised
August 17, 2018	ING-CC-0001	Erythropoiesis Stimulating Agents	Revised
August 17, 2018	ING-CC-0004*	H.P. Acthar Gel (repository corticotropin injection)	Revised

August 17, 2018	ING-CC-0019*	Zoledronic Acid Agents	Revised
August 17, 2018	ING-CC-0022	Vimizim (elosulfase alfa)	Revised
August 17, 2018	ING-CC-0023	Naglazyme (galsulfase)	Revised
August 17, 2018	ING-CC-0031*	Intravitreal Corticosteroid Implants	Revised
November 16, 2018	ING-CC-0054	Selected Progestins	Revised
November 16, 2018	ING-CC-0067*	Prostacyclin Infusion and Inhalation Therapy	Revised
November 16, 2018	ING-CC-0072*	Selective Vascular Endothelial Growth Factor (VEGF) Antagonists	Revised
November 16, 2018	ING-CC-0076*	Nulojix (belatacept)	Revised
November 16, 2018	ING-CC-0056*	Selected Injectable 5HT3 Antiemetic Agents	Revised
November 16, 2018	ING-CC-0059*	Selected Injectable NK-1 Antiemetic Agents	Revised
November 16, 2018	ING-CC-0062	Tumor Necrosis Factor Antagonists	Revised
August 17, 2018	ING-CC-0009	Lemtrada (alemtuzumab)	Revised
August 17, 2018	ING-CC-0014	Beta Interferons and Glatiramer Acetate for Treatment of Multiple Sclerosis	Revised
August 17, 2018	ING-CC-0015	Infertility Agents	Revised
August 17, 2018	ING-CC-0016	Vivitrol (extended-release, injectable naltrexone) Injection	Revised
August 17, 2018	ING-CC-0025*	Aldurazyme (laronidase)	Revised
August 17, 2018	ING-CC-0030	Implantable and ER Buprenorphine Containing Agents	Revised
August 17, 2018	ING-CC-0033	Xolair (omalizumab)	Revised
November 16, 2018	ING-CC-0040*	Prialt (ziconotide)	Revised
November 16, 2018	ING-CC-0047	Trogarzo (ibalizumab-uiyk)	Revised
November 16, 2018	ING-CC-0050	Monoclonal Antibodies to Interleukin-23	Revised
November 16, 2018	ING-CC-0057	Krystexxa (pegloticase)	Revised
November 16, 2018	ING-CC-0063	Stelara (ustekinumab)	Revised
November 16, 2018	ING-CC-0064	Interleukin-1 Inhibitors	Revised
November 16, 2018	ING-CC-0066	Monoclonal Antibodies to Interleukin-6	Revised
November 16, 2018	ING-CC-0068	Growth hormone	Revised

November 16, 2018	ING-CC-0071	Entyvio (vedolizumab)	Revised
November 16, 2018	ING-CC-0073	Alpha-1 Proteinase Inhibitor Therapy	Revised
November 16, 2018	ING-CC-0075	Rituxan (rituximab) for Non-Oncologic Indications	Revised
August 17, 2018	ING-CC-0002*	Colony Stimulating Factor Agents	Revised
August 17, 2018	ING-CC-0003	Immunoglobulins	Revised
August 17, 2018	ING-CC-0011	Ocrevus (ocrelizumab)	Revised
August 17, 2018	ING-CC-0020	Tysabri (natalizumab)	Revised
August 17, 2018	ING-CC-0032	Botulinum Toxin	Revised
November 16, 2018	ING-CC-0041	Soliris (eculizumab)	Revised
November 16, 2018	ING-CC-0043	Monoclonal Antibodies to Interleukin-5	Revised
November 16, 2018	ING-CC-0046	Zinplava (bezlotoxumab)	Revised
November 16, 2018	ING-CC-0051	Enzyme Replacement Therapy for Gaucher Disease	Revised
November 16, 2018	ING-CC-0052*	Dihydroergotamine (DHE) Injection	Revised
November 16, 2018	ING-CC-0053	Injectable Hydroxyprogesterone for prevention of preterm birth	Revised
November 16, 2018	ING-CC-0055	Fuzeon (enfuvirtide)	Revised
November 16, 2018	ING-CC-0058	Octreotide Agents	Revised
November 16, 2018	ING-CC-0069	Egrifta (tesamorelin)	Revised
November 16, 2018	ING-CC-0078	Orencia (abatacept)	Revised
November 16, 2018	ING-CC-0061	GnRH Analogs for the treatment of non-oncologic indications	Annual review
August 17, 2018	ING-CC-0008	Testopel (testosterone subcutaneous implant)	Annual review
November 16, 2018	ING-CC-0065	Antihemophilic Factors and Clotting Factors	Annual review
November 16, 2018	ING-CC-0006	Hyaluronan Injections	Annual review
August 17, 2018	ING-CC-0007	Synagis (palivizumab)	Annual review
August 17, 2018	ING-CC-0012	Brineura (cerliponase alfa)	Annual review
August 17, 2018	ING-CC-0017	Xiaflex (clostridial collagenase histolyticum) injection	Annual review
August 17, 2018	ING-CC-0018	Lumizyme (alglucosidase alfa)	Annual review
August 17, 2018	ING-CC-0021	Fabrazyme (agalsidase beta)	Annual review

August 17, 2018	ING-CC-0024	Elaprase (idursufase)	Annual review
August 17, 2018	ING-CC-0028	Benlysta (belimumab)	Annual review
October 23, 2018	ING-CC-0029	Dupixent (dupilumab)	Annual review
August 17, 2018	ING-CC-0034	Agents for Hereditary Angioedema	Annual review
August 17, 2018	ING-CC-0035	Duopa (carbidopa and levodopa enteral suspension)	Annual review
August 17, 2018	ING-CC-0036	Naltrexone Implantable Pellets	Annual review
August 17, 2018	ING-CC-0037	Kanuma (sebelipase alfa)	Annual review
November 16, 2018	ING-CC-0039	GamaSTAN (immune globulin (human))	Annual review
November 16, 2018	ING-CC-0044	Exondys 51 (eteplirsen)	Annual review
November 16, 2018	ING-CC-0045	Increlex (mecasermin)	Annual review
November 16, 2018	ING-CC-0048	Spinraza (nusinersen)	Annual review
November 16, 2018	ING-CC-0049	Radicava (edaravone)	Annual review
November 16, 2018	ING-CC-0064	Interleukin-1 Inhibitors	Annual review
November 16, 2018	ING-CC-0070	Jetrea (ocriplasmin)	Annual review
November 16, 2018	ING-CC-0079	Strensiq (asfotase alfa)	Annual review

Note: Criteria marked with an * may be perceived as more restrictive.